newsfilter
← Latest News
GlobeNewswire·

Picard Medical / SynCardia Reports Revenue Growth Based on Top-line Results for the First Quarter 2026

  • Picard Medical, Inc. announced preliminary, unaudited first-quarter 2026 revenues of $1.1 million as of March 31, 2026.
  • Revenue increased 79.9% compared to $0.6 million in the same period of 2025.
  • Growth was driven by higher sales of the SynCardia Total Artificial Heart (STAH) due to favorable U.S. reimbursement & economic conditions.
  • Increased driver rental income resulted from pricing adjustments implemented during the quarter.
  • CEO Patrick NJ Schnegelsberg highlighted progress in commercial initiatives & increased STAH utilization as a bridge to transplant.
  • The company plans to file full financial results in a Form 10-Q with the SEC on or before May 15, 2026.
  • SynCardia remains the only commercially available total artificial heart in the U.S. & Canada with over 2,100 implants in 27 countries.
  • The preliminary financial data has not been audited by the Company's independent registered public accounting firm.